Table 3 Variation of process measures according to the clinical settings in acute coronary syndrome and acute heart failure

Upon admission

≥6

1

Aspirin at arrival

4–5

1

Assessment of cardiovascular risk factors

2–3

4

Assessment of 12 lead ECG, P2Y12 inhibitors before PCI.

1

7

Registration of start of symptoms, assessment of cardiovascular antecedents.

Acute setting

≥6

2

Time for primary PCI/Timely performed PCI, time for fibrinolytic therapy.

4–5

0

2–3

2

Early beta-blockers use, immediate angiography for cardiac arrest.

1

9

Peri-procedural admission of morphine or alike, radial access.

During hospitalization / at discharge

≥6

5

Aspirin at discharge, high-intensity statins prescription.

4–5

3

P2Y12 inhibitors at discharge, cardiac rehabilitation.

2–3

4

Hypertension control, risk stratification with noninvasive stress testing.

1

7

Mention about DAPT duration, provision of nutritional advice.

Acute setting

≥3

0

2

1

Chest radiograph or another diagnostic test

1

2

Medical history documentation, physical examination

During hospitalization / at discharge

≥3

4

Beta-blocker therapy for HFrEF, ACE inhibitor, ARB or ARNI therapy for HFrEF.

2

2

Daily assessment of blood chemistry levels, post-discharge appointment.

1

11

ARNI therapy for HFrEF, MRA therapy for HFrEF.